[go: up one dir, main page]

PE20011163A1 - Tratamiento de trastornos renales - Google Patents

Tratamiento de trastornos renales

Info

Publication number
PE20011163A1
PE20011163A1 PE2001000305A PE2001000305A PE20011163A1 PE 20011163 A1 PE20011163 A1 PE 20011163A1 PE 2001000305 A PE2001000305 A PE 2001000305A PE 2001000305 A PE2001000305 A PE 2001000305A PE 20011163 A1 PE20011163 A1 PE 20011163A1
Authority
PE
Peru
Prior art keywords
treatment
kidney disorders
agent
dihydropyridine
endothelin
Prior art date
Application number
PE2001000305A
Other languages
English (en)
Inventor
Adrian Paul Foster
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20011163A1 publication Critical patent/PE20011163A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL USO DE UN BLOQUEANTE DE LOS CANALES DE CALCIO TAL COMO DIHIDROPIRIDINA, BESILATO DE AMLODIPINO UTILIZANDO DE 0,1 mg A 1,5mg; OPCIONALMENTE EN PRESENCIA DE UN AGENTE ANTIHIPERTENSIVO DE UNA CLASE DIFERENTE TAL COMO UN AGENTE QUE REDUCE EL EFECTO DE LA ENDOTELINA, ANGIOTENSINA; PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA INSUFICIENCIA RENAL CRONICA EN ANIMALES NORMOTENSOS
PE2001000305A 2000-04-04 2001-04-02 Tratamiento de trastornos renales PE20011163A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008332.9A GB0008332D0 (en) 2000-04-04 2000-04-04 Treament

Publications (1)

Publication Number Publication Date
PE20011163A1 true PE20011163A1 (es) 2001-11-12

Family

ID=9889228

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000305A PE20011163A1 (es) 2000-04-04 2001-04-02 Tratamiento de trastornos renales

Country Status (12)

Country Link
EP (1) EP1284719A2 (es)
JP (1) JP2003528927A (es)
AR (1) AR027763A1 (es)
AU (1) AU2001239510A1 (es)
BR (1) BR0109783A (es)
CA (1) CA2403950A1 (es)
GB (1) GB0008332D0 (es)
MX (1) MXPA02009819A (es)
PA (1) PA8514601A1 (es)
PE (1) PE20011163A1 (es)
TN (1) TNSN01051A1 (es)
WO (1) WO2001074390A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001294354A1 (en) * 2000-12-29 2002-07-16 Bioorganics B.V. Process for making amlodipine, derivatives thereof, and precursors therefor
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
AT5874U1 (de) * 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
SI1443917T1 (sl) * 2001-11-07 2006-06-30 Synthon Bv Tablete tamsulozina
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
CO5400144A1 (es) * 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
US7423009B2 (en) 2002-09-30 2008-09-09 Kowa Company, Ltd. Method for treatment of kidney diseases
BRPI0406987A (pt) 2003-01-31 2006-01-10 Sankyo Co Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral
US20080268049A1 (en) * 2005-02-11 2008-10-30 Dhaliwal Mona Stable Solid Dosage Forms of Amlodipine and Benazepril
MX2007011119A (es) 2005-03-15 2007-11-14 Lupin Ltd Composiciones farmaceuticas de amlodipino y benazepril.
RU2398447C2 (ru) * 2005-04-29 2010-09-10 Хилл'С Пет Ньютришн, Инк. Способы увеличения продолжительности жизни кошек
KR20180123021A (ko) * 2016-03-24 2018-11-14 다이이찌 산쿄 가부시키가이샤 신질환의 치료를 위한 의약

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8710493D0 (en) * 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
DE69105040T2 (de) * 1990-05-31 1995-03-23 Pfizer, Inc., New York, N.Y. Arzneimittel gegen Impotenz.
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
CA2124445A1 (en) * 1991-11-26 1993-06-10 James W. Young Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
PT804229E (pt) * 1995-03-16 2003-06-30 Pfizer Utilizacao de amlodipina de um dos seus sais ou defelodipina em combinacao com um inibidor da en zima de conversao da angiotensina (ace) para no fabrico de um medicamento destinado ao tratamento da insuficiencia cardiaca congestiva nao isquemica
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Also Published As

Publication number Publication date
TNSN01051A1 (fr) 2005-11-10
CA2403950A1 (en) 2001-10-11
WO2001074390A3 (en) 2002-05-30
JP2003528927A (ja) 2003-09-30
MXPA02009819A (es) 2003-03-27
AU2001239510A1 (en) 2001-10-15
PA8514601A1 (es) 2002-08-26
GB0008332D0 (en) 2000-05-24
EP1284719A2 (en) 2003-02-26
BR0109783A (pt) 2003-01-21
AR027763A1 (es) 2003-04-09
WO2001074390A2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
AR028423A1 (es) Inhibidores de la replicacion del hiv
NL300343I2 (nl) 6-alfa, 9-alfa-difluor-17-alfa-(2-furanylcarboxyl)oxy-11-beta-hydroxy-16-alfa-methyl-3-oxo-androst-1,4-dieen-17-carbothionzuur-s-fluormethylester als een ontsteking-remmend middel
SI3808743T1 (sl) Pirimidini, ki inhibirajo replikacijo HIV
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
PE20011163A1 (es) Tratamiento de trastornos renales
FR2804025B1 (fr) Compositions pharmaceutiques stabilisees
CY2007031I1 (el) Συνθεση στοματικης δοσολογιας παρατεταμενης απελευθερωσης
DE60028536D1 (de) In der Mundhöhle schnell zerfallende orale feste Verabreichungsform
IS6686A (is) Hýdrógel-drifið lyfjaskömmtunarform
AU3652102A (en) Compounds and their uses
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
EE200100293A (et) Kontrollitud vabanemisega ravivorm, mis sisaldab GnRH-II
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
IS2170B (is) Sýklópentanóindól, efnablöndur sem innihalda slíkefnasambönd og meðhöndlunaraðferðir
ATE355271T1 (de) Pharmazeutische zusammensetzung
TW200730202A (en) Solid dosage form
DE60143363D1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
DE60129238D1 (de) Pharmazeutische zusammensetzung
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
IS6690A (is) Trísýklísk 2-pýridon efnasambönd, nýtileg sem HIVvíxlritatálmar
NO20040857L (no) Ny oral forlenget frigivelses doseringsform.

Legal Events

Date Code Title Description
FC Refusal